Objective Bio raises $70 million to assist scale its tech for enhancing the development of targeted cancer treatments

Objective Bio raises $70 million to assist scale its tech for enhancing the development of targeted cancer treatments

California-based start-up Mission Bio has raised a new$70 million Series C financing round, led by Novo Growth and including participation from Soleus Capital and existing investors Mayfield, Cota and Agilent. Objective Bio will use the funding to scale its Tapestri Platform, which uses the company’s work in single-cell multi-omics innovation to help enhance scientific […]…